ENANTA PHARMACEUTICALS INC
For the period ended Dec 31, 2024. Filed Feb 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2024 · Filed Feb 12, 2025
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2024-06-30; filed 2024-08-07.
0000950170-24-092714
Item 1A. Risk FactorsOther InformationCurrent report: 10-Q
Period ended 2024-12-31; filed 2025-02-12.
0000950170-25-018810
Item 1A. Risk FactorsOther InformationThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 8 previous paragraphs and 5 current paragraphs.
2 unchanged; 3 reworded; 0 added; 2 removed; 1 previous and 0 current paragraphs rearranged.
Tables are not compared: 0 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Removed paragraphs (2)
Previous report
On June 13, 2024, Jay R. Luly, Ph.D., our President, Chief Executive Officer and Director, adopted a Rule 10b5-1 trading plan providing for the sale of up to 140,250 shares of common stock vested under outstanding stock options, which are set to expire on November 20, 2024, so long as the market price of our common stock is higher than certain minimum threshold prices specified in the plan in various periods between September 16, 2024 and May 30, 2025, or such earlier date as all authorized sales under the plan are completed;
Previous report
On June 14, 2024, Paul J. Mellett, our Chief Financial and Administrative Officer, adopted a Rule 10b5-1 trading plan providing for the sale of up to 46,250 sharesof our common stock, including shares vested under outstanding stock options, which are set to expire on November 20, 2024, as well as shares vested under certain performance stock units and restricted stock units, so long as the market price of our common stock is higher than certain minimum threshold prices specified in the plan in various periods between September 16, 2024 and May 30, 2025, or such earlier date as all authorized sales under the plan are completed;
Reworded paragraphs (3)
Previous wording
Our business faces significant risks and uncertainties. Certain factors may have a material adverse effect on our business prospects, financial condition and results of operations, and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to consider the detailed discussion of risk factors included in our 2023 Form 10-K and our Quarterly Report for the period ended December 31, 2023.
Current wording
Our business faces significant risks and uncertainties. Certain factors may have a material adverse effect on our business prospects, financial condition and results of operations, and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to consider the detailed discussion of risk factors included in our 2024 Form 10-K.
Previous wording
Except as set forth below, there have been no material changes to such risk factors during the quarter ended June 30, 2024. Other events that we do not currently anticipate or that we currently deem immaterial may also affect our business, prospects, financial condition and results of operations.
Current wording
There have been no material changes to such risk factors during the quarter ended December 31, 2024. Other events that we do not currently anticipate or that we currently deem immaterial may also affect our business, prospects, financial condition and results of operations.
Previous wording
Except as set forth above, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-rule 10b5-1 trading arrangement,” as each term is defined in item 408(a) of Regulation S-K.
Current wording
Rule 10b5-1 Trading Arrangements. During the three months ended December 31, 2024, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-rule 10b5-1 trading arrangement,” as each term is defined in item 408(a) of Regulation S-K.
Rearranged previous paragraphs (1)
Previous report — wording carried elsewhere
Rule 10b5-1 Trading Arrangements. During the three months ended June 30, 2024, the following officers (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted a “Rule 10b5-1 trading arrangement” as that term is defined in Item 408(a) of Regulation S-K, all of which were entered into during an open trading window in accordance with the Company’s Securities Trading Policy and all of which were intended to satisfy Rule 10b5-1(c):